Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Purity: ≥98%
Betulinic acid (also known as ALS-357; LS-357; Mairin; Lupatic acid; Betulic acid) is a naturally occuring pentacyclic triterpenoid extracted from Syzigium claviflorum that displays anti-HIV and antitumor activity. Through an EC50 of 1.4 μ M, Betulinic acid inhibits HIV-1. By directly triggering the mitochondrial pathway of apoptosis in tumor cells in a way that is independent of both CD95 and p53, Betulinic acid specifically causes apoptosis in these cells. With an EC50 of 1.04 μM, Betulinic acid also exhibits TGR5 agonist activity.
Targets |
Topoisomerase I ( IC50 = 5 μM ); HIV-1 ( IC50 = 1.4 μM ); NF-κB
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Enzyme Assay |
The 25-mer annealed duplex consisting of oligonucleotide-1 and oligonicleotide-2 is subjected to an 8°C incubation period with 25 or 50 units of rat liver topoisomerase I, either in the presence or absence of betulinic acid in the binding buffer. Following incubation, the reaction mixtures are electrophoresed in a 7% non-denaturing polyacrylamide gel in 0.167 × TBE buffer at 4 °C. Ethidium bromide is then used to stain the DNA bands.
|
|
Cell Assay |
The assay makes use of CCK-8. After being grown at a density of 2 × 103 cells/well in 96-well plates, MDA-MB-231 cells are treated with DMSO vehicle or different concentrations of betulinic acid (5 µM to 160 µM) in 100 µL of medium for the specified durations. Following the treatment phase, 110 µL of medium containing 10 µL of the CCK-8 mixture is added to each well, and the plates are incubated at 37°C for one hour and thirty minutes. With the aid of a microplate reader, the absorbance at 450 nm wavelength is determined[2].
|
|
Animal Protocol |
|
|
References |
|
Molecular Formula |
C30H48O3
|
|
---|---|---|
Molecular Weight |
456.7
|
|
Exact Mass |
456.36
|
|
Elemental Analysis |
C, 78.90; H, 10.59; O, 10.51
|
|
CAS # |
472-15-1
|
|
Appearance |
Solid powder
|
|
SMILES |
CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)C(=O)O
|
|
InChi Key |
QGJZLNKBHJESQX-FZFNOLFKSA-N
|
|
InChi Code |
InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1
|
|
Chemical Name |
(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 20~35.7 mg/mL (43.8~78.2 mM)
Ethanol: 10 mg/mL (~21.9 mM) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1896 mL | 10.9481 mL | 21.8962 mL | |
5 mM | 0.4379 mL | 2.1896 mL | 4.3792 mL | |
10 mM | 0.2190 mL | 1.0948 mL | 2.1896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00346502 | Withdrawn | Drug: 20% betulinic acid ointment Drug: BA |
Dysplastic Nevus Syndromey | University of Illinois at Chicago | January 2006 | Phase 1 Phase 2 |